Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Closing of Non-Brokered Private Placement for $1.7 Million. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News CRISPR Therapeutics AG CRSP

Healthcare Biotechnology
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has... see more

Current News (NDAQ:CRSP)

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

GlobeNewswire 9 days ago

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2026

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112(TM)) in Autoimmune Diseases and Hematologic Malignancies

GlobeNewswire December 22, 2025

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Canada NewsWire December 9, 2025

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

GlobeNewswire November 10, 2025

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

GlobeNewswire November 8, 2025

CRISPR Therapeutics Presents New Preclinical Data for CTX460(TM) Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase(TM) Editing Platform

GlobeNewswire October 10, 2025

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

GlobeNewswire October 1, 2025

CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe

GlobeNewswire September 22, 2025
View More News ››

Opinion & Analysis (NDAQ:CRSP)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CRSP)

CRISPR Therapeutics AG (NASDAQ:CRSP): A Pioneering Gene Edit

http://beyondspx.com/2024/07/31/crispr-therapeutics-ag-nasdaqcrsp-a-pioneering-gene-editing-company-poised-for-continued-growth/
MikeTester - August 2, 2024

RE:regrets

Lol if you think it's a 1000 dollar stock it's definitely not too late. 52.22 at close today...
CreatingApe - May 8, 2024

RE: Switzerland-based biotechnology leader

Eventually, it will be like owning a solid ETF. I view it similar to an ARKK or TSLA....it just requires some long term paitience! ...
foofadooo - August 25, 2022

Switzerland-based biotechnology leader

portfolio of therapies across a range of disease areas, including treatments for blood disorders, specialized cancers and other rare...
jw1trader - August 24, 2022

$4 billion CRISPR is a Switzerland-based biotechnology

biotechnology leader known for its cutting-edge platform to support gene editing and related development of genomic DNA medicines. It has...
Lisaslab - August 24, 2022

RE:regrets

IMHO.....it's not to late there will br many growth stocks springboard off CRSPR....CRBU... is a good example... foof
foofadooo - August 19, 2021
View more Bullboard ››

Graphite One Inc.

Graphite One Inc.

Graphite One Inc. operates as mineral exploration company in the United States. Its primary project is the Graphite Creek ...
View More »

Podcasts